Skip to main content
Premium Trial:

Request an Annual Quote

Products: OGT's SureSeq Solid Tumor Panel

Premium

Oxford Gene Technologies has launched a targeted sequencing service for tumor profiling. The SureSeq Solid Tumor Panel service analyzes 58 cancer-related genes to detect novel and actionable mutations in breast, prostate, ovarian, lung, and colorectal cancers.

The panel was developed in collaboration with researchers from the University of Southampton, University of Birmingham, and CIS Healthcare as part of a £1.16 ($1.75) million funding award from UK's Technology Strategy Board's Stratified Medicines program.

Also included in the program was a panel launched by the University of Oxford earlier this year and a panel still in development by Source BioScience (CSN 1/2/2013).

OGT's panel uses Agilent's SureSelect hybridization technology and was validated on both fresh frozen and formalin-fixed, paraffin-embedded tissue against blinded, previously genotyped samples.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.